US 11,939,593 B2
Compositions and methods for improving embryo development
Charles A. Easley, IV, Athens, GA (US); and Anthony W. S. Chan, Atlanta, GA (US)
Assigned to UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., Athens, GA (US); and EMORY UNIVERSITY, Atlanta, GA (US)
Appl. No. 17/265,157
Filed by University of Georgia Research Foundation, Inc., Athens, GA (US); and Emory University, Atlanta, GA (US)
PCT Filed Aug. 1, 2019, PCT No. PCT/US2019/044589
§ 371(c)(1), (2) Date Feb. 1, 2021,
PCT Pub. No. WO2020/028617, PCT Pub. Date Feb. 6, 2020.
Claims priority of provisional application 62/713,182, filed on Aug. 1, 2018.
Prior Publication US 2021/0340493 A1, Nov. 4, 2021
Int. Cl. C12N 5/073 (2010.01); C12N 5/076 (2010.01); C12N 15/90 (2006.01)
CPC C12N 5/0604 (2013.01) [C12N 5/061 (2013.01); C12N 15/90 (2013.01); C12N 2506/02 (2013.01); C12N 2506/45 (2013.01); C12N 2510/00 (2013.01); C12N 2517/10 (2013.01)] 20 Claims
 
1. A method of improving embryo development comprising administering into an oocyte or male gamete, or a fertilized embryo an effective amount of a compound that increases bioavailability of a TET protein and a sperm extract to improve development of the fertilized embryo, or a subsequent embryo resulting from fertilization of the oocyte by the male gamete.